Advanced Search:
Equity Index Forex Crypto Commodity

UTHR - United Therapeutics Corporation

$255.14  20.81 (8.88%)

Updated: 17:10 May 1, 2024 EST

Next Hour's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Session's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Week's AI Forecast

N/A

Trend's Accuracy (AI)

N/A

United Therapeutics Corporation's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

UNITED THERAPEUTICS CORPORATION - HISTORICAL DATA 6M

  • Last price

    $ 255.14

  • Daily change

    $ 20.81

  • Previous Close

    $ 234.33

  • Last Updated

    17:10 May 1, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 -0.08 0.18 0.05 0.05

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 1.03 1.28 1.16 1.17

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
N/A 10.88% 39.35% 57.55%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0 -100% 235.42 -0.16% 235.79 2.94% 229.06

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
1.47 65.03 0.82 59.51

United Therapeutics Corporation Technical Analysis News

United Therapeutics Corporation

1040 Spring Street
Silver Spring, MD 20910
United States
301 608 9292
http://www.unither.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 950
Description

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Corporate Governance

United Therapeutics Corporation’s ISS Governance QualityScore as of July 1, 2021 is 3. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 3; Compensation: 4.

UNITED THERAPEUTICS CORPORATION'S HOLDERS RANK

List of holders with stock participation in United Therapeutics Corporation.

Holder Rank Holder Shares Date Reported % Out Value